Bookmark

Add to MyYahoo RSS

Alexion Pharmaceuticals News

News on Alexion Pharmaceuticals (Ticker: ALXN) continually updated from thousands of sources around the net.

Friday Jul 18 | Investor's Business Daily

Will New Drug Give Alexion Pharmaceuticals A Boost?

In October, the FDA awarded breakthrough therapy designation for ALXN1101, a new drug Alexion is developing to treat hypophosphatasia, or HPP, an ultrarare metabolic disorder.

Comment?

Related Topix: Biotech, Taligen Therapeutics, Medicine, Healthcare Industry

Friday Jul 18 | Forbes.com

Friday Sector Leaders: Utilities, Healthcare

The best performing sector as of midday Friday is the Utilities sector, up 1.1%.

Comment?

Related Topix: Pacific Star Communications, Pinnacle West Capital Corporation, Energy, Financial Markets, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Taligen Therapeutics

Wed Jul 16, 2014

Sys-Con Media

Pegasystems Appoints Anne Warner General Counsel and Chief Compliance Officer

Ms. Warner will be responsible for leading Pegasystems' global legal and compliance groups.

Comment?

Related Topix: Pegasystems, Software, Chordiant Software, Startups, Biotech, Taligen Therapeutics, Medicine, Healthcare Industry, Cheshire, CT

Customer Interaction Solutions

Alexion Announces the Appointments of David R. Brennan, M. Michele...

Alexion Pharmaceuticals, Inc. today announced the appointments of David R. Brennan, M. Michele Burns and Christopher J. Coughlin to the Company's Board of Directors, effective immediately.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, AstraZeneca, AstraZeneca Group, Merck , Insurance, Marsh and Mclennan Companies

Thu Jul 10, 2014

AmericanBankingNews.com

Zacks Downgrades Alexion Pharmaceuticals to Neutral

They currently have a $173.00 target price on the stock. Zacks 's price target would suggest a potential upside of 6.21% from the stock's previous close.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics

The Motley Fool

3 Stocks Near 52-Week Highs Worth Selling

With the S&P 500 and Dow Jones Industrial Average making new records on a nearly weekly basis, it should come as no surprise that new 52-week highs outnumber new lows by a lot .

Comment?

Related Topix: Financial Markets, Biotech, Taligen Therapeutics, Medicine, Healthcare Industry

Customer Interaction Solutions

Alexion Pharmaceuticals to Report Second Quarter 2014 Results on Thursday, July 24, 2014

Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the second quarter ended June 30, 2014 on Thursday, July 24, 2014 before the US financial markets open.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics

Thu Jul 03, 2014

Benzinga

Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

Large-cap biotech stocks should see healthy second-quarter results driven by strong demand and new products, a Citi analyst said Thursday.

Comment?

Related Topix: Financial Markets, Biotech, Taligen Therapeutics, Medicine, Healthcare Industry, Amgen, Enbrel, Etanercept (generic)

Tue Jul 01, 2014

Forbes.com

Tuesday Sector Leaders: Healthcare, Technology & Communications

In afternoon trading on Tuesday, Healthcare stocks are the best performing sector, up 1.5%.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, Regeneron Pharmaceuticals, Healthcare Industry, Taligen Therapeutics, Computers, Seagate Technology

Californiaexaminer.net

Unusual Option Trades: Amicus Therapeutics

It appears biopharm stocks are hot, and getting hotter. Two of today's most unusual, large option trades involve Amicus Therapeutics , and Alexion Pharmaceuticals .

Comment?

Related Topix: Amicus, Startups, Financial Markets, Biotech, Taligen Therapeutics, Medicine, Healthcare Industry

Fri Jun 27, 2014

Forbes.com

Friday Sector Laggards: Materials, Healthcare

The worst performing sector as of midday Friday is the Materials sector, showing a 0.4% loss.

Comment?

Related Topix: Rubber-Plastics, Manufacturing, Dow Chemical, Chemicals, Financial Markets, Biotech, Taligen Therapeutics, Medicine, Healthcare Industry, Regeneron Pharmaceuticals

Mon Jun 23, 2014

AmericanBankingNews.com

Alexion Pharmaceuticals CEO Leonard Bell Sells 90,280 Shares

Alexion Pharmaceuticals CEO Leonard Bell unloaded 90,280 shares of the company's stock on the open market in a transaction dated Friday, June 20th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics

The Motley Fool

Why Lorillard, Inc., Alexion Pharmaceuticals, Inc., and Coach, Inc. Are Today's 3 Worst Stocks

The benchmark index certainly didn't get any help from the likes of Lorillard, , which ended as three of the worst stocks in the entire S&P.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Financial Markets

Investor's Business Daily

Alexion and Cincinnati Children's Launch Rare Disease Innovation Fund

CHESHIRE, Conn. & CINCINNATI-- -- Alexion Pharmaceuticals, Inc. and Cincinnati Children's Hospital Medical Center today announced the establishment of a collaboration and fund for the advancement of research in rare disease.

Comment?

Related Topix: Cheshire, CT, Biotech, Medicine, Healthcare Industry, Cincinnati Children's Hospital Medical Center, Hospital Administration

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••